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Highlights 
 Deaths from opioid overdose can be prevented by prompt injection of the 
opiate antagonist naloxone 
 
 After 40 years of injection-based naloxone, a concentrated naloxone nasal 
spray is now approved 
 
 Systematic review finds 3 potential injection-free naloxone routes: nasal, 
sublingual & buccal 
 
 Alongside concentrated nasal naloxone, buccal may have distinct advantages 
as future product  
 
 Wider pre-provision of naloxone across the community is essential; all three 
routes warrant study 
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Abstract 
Introduction: Deaths from opioid overdose can be prevented through administration 
of the antagonist naloxone, which has been licensed for injection since the 1970s. To 
support wider availability of naloxone in community settings, novel non-injectable 
naloxone formulations are being developed, suitable for emergency use by non-
medical personnel.  Objectives: 1) Identify candidate routes of injection-free 
naloxone administration potentially suitable for emergency overdose reversal; 2) 
consider pathways for developing and evaluating novel naloxone formulations.  
Methods: A three-stage analysis of candidate routes of administration was 
conducted: 1) Assessment of all 112 routes of administration identified by FDA 
against exclusion criteria. 2) Scrutiny of empirical data for  identified candidate 
routes, searching PubMed and WHO International Clinical Trials Registry Platform 
using search terms “naloxone AND [route of administration]”. 3) Examination of 
routes for feasibility and against the inclusion criteria.  Results: Only three routes of 
administration met inclusion criteria: nasal, sublingual and buccal. Products are 
currently in development and being studied. Pharmacokinetic data exist only for 
nasal naloxone, for which product development is more advanced, and one 
concentrated nasal spray was granted licence in the US in 2015. However, buccal 
naloxone may also be viable and may have different characteristics.  Conclusion: 
After 40 years of injection-based naloxone treatment, non-injectable routes are finally 
being developed. Nasal naloxone has recently been approved and will soon be field-
tested, buccal naloxone holds promise, and it is unclear what sublingual naloxone will 
contribute. Development and approval of reliable non-injectable formulations will 
facilitate wider naloxone provision across the community internationally. 
 
KEYWORDS: naloxone; drug development; heroin; opioid; overdose; deaths; nasal; 
buccal; sublingual.   
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1. INTRODUCTION 
1.1. An excess of deaths 
 Heroin/opioid overdose deaths represent a major international public health 
concern (UNODC/WHO, 2013). Even in countries with low prevalence of opioid use 
relative to consumption of other illicit drugs, opioids contribute disproportionately to 
overdose fatalities (Degenhardt et al., 2011; WHO, 2014). In the United States (US), 
there has been a greater than fourfold increase in overdose deaths from prescription 
opioids since 1999, accounting for 16,651 deaths in 2010 alone (CDC, 2012; Volkow 
et al., 2014), as well as a simultaneous rise in heroin overdose deaths from 2007 
onwards (Calcaterra et al., 2013). In the United Kingdom (UK), a 64% rise in 
heroin/morphine deaths was recorded for England and Wales between 2012 and 
2014 (ONS, 2015).   
1.2. Wider provision of naloxone 
 In response, there are increasing calls for wider access to the opioid 
antagonist naloxone (ACMD, 2012; UNODC/WHO, 2013). The World Health 
Organization (WHO) launched new guidelines on the prevention of opioid overdose 
deaths in 2014, recommending that “people likely to witness an opioid overdose 
should have accesss to naloxone” (p. x) (WHO, 2014).  
 In the US, the National Institute on Drug Abuse (NIDA) made funding 
available for the development of novel injection-free naloxone products (Volkow et 
al., 2014) and, in November 2015, the US Food and Drug Administration (FDA) gave 
approval to a new nasal spray of concentrated naloxone solution (FDA, 2015), 
thereby giving the first regulatory product approval world-wide for a non-injectable 
naloxone product.  
1.3. The promise of non-injectable naloxone 
 The notion of non-injectable formulations of naloxone is attractive: naloxone 
without needles would have many advantages. Firstly, medications which need to be 
injected are intimidating for laypersons to use in non-medical settings (Beletsky et al., 
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2012). Secondly, with use of naloxone by injection, there is the risk of needle-stick 
injury and contraction of blood-borne diseases (e.g., hepatitis C, HIV), which are 
highly prevalent among this patient group. Thirdly, non-injectable naloxone  could 
more easily be provided to a much wider intervention workforce (e.g., hostel staff, 
outreach workers, police, etc.).  
 New methods of delivery for naloxone  need to be suitable for emergency use 
by non-medical personnel in community-based settings. Furthermore, formulations 
should be developed with longer shelf-life, especially in view of the pre-placement of 
these naloxone products to community and families and other non-hospital settings. 
Naloxone also needs to be absorbed rapidly, given the emergency situation, in 
quantity sufficient to effect quick reversal of  opioid-induced respiratory depression.  
The reference for any candidate non-injectable routes is injectable naloxone, 
administered by the licensed intramuscular (IM), intravenous (IV), and subcutaneous 
(S/C) routes (WHO, 2014). When administered by the IM or S/C routes, naloxone 
typically reverses opioid action within 3-7 minutes; whereas the effect from IV 
administration has an onset typically within 2 minutes (UNODC/WHO, 2013). With 
long-standing approval for, and experience with, naloxone in injectable form, this sets 
the standard against which possible non-injectable formulations need to be 
measured (Hertz, 2012). In this review, we examine the options for non-injectable 
naloxone with potential application for wider community-based opioid overdose 
reversal.  
2. MATERIAL AND METHODS 
 A three-stage approach has been taken (see Figure 1). The first stage was an 
examination of all 112 routes of drug administration listed by the US Food and Drug 
Administration (FDA, 1992)updated 2014). For each of the 112 possible routes of 
administration, we considered the potential applicability as a viable non-injectable 
route for emergency naloxone delivery by non-medical personnel (see 
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Supplementary Material1). We thus identified routes as unsuitable according to five 
exclusion criteria:  
i) if the drug administration is by injection (or similar invasive procedure);  
ii) if the route is only relevant to medical procedures or requires medical 
training; 
iii) if the route is not publicly acceptable for administration by non-medical 
bystanders (e.g., rectal or vaginal administration); 
iv) if the route does not produce adequate systemic drug concentrations; 
v) if the route does not produce sufficiently rapid drug absorption relative to 
parenteral administration (Hertz, 2012). 
 The second stage was to systematically search PubMed and the WHO 
International Clinical Trials Registry Platform for the potential candidate routes of 
administration that had emerged from the first stage. The search term “naloxone 
AND [route of administration]” (e.g., “naloxone AND (nose OR nasal OR intranasal)”) 
was used for each route across the electronic databases (see Supplementary 
Material2 for search protocol). R.M. conducted the search and assessed retrieved 
studies for eligibility under supervision of J.S. Relevant original research studies that 
were published in English language and reported on the outcomes of in vivo 
naloxone administration (e.g., overdose reversals, pharmacokinetics/-dynamics data) 
in humans or animals were included in our analysis (see Figure 2 for PRISMA 
diagram).  
                                                        
1 Supplementary material can be found by accessing the online version of this paper at 
http://dx.doi.org and by entering doi:...  
 
 
2 Supplementary material can be found by accessing the online version of this paper at 
http://dx.doi.org and by entering doi:... 
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 The third stage, for remaining potential non-injectable routes of 
administration, comprised a more rigorous examination of the evidence against the 
inclusion criteria (see also Table 1): 
i) the route is suitable for overdose emergency situation;  
ii) the route does not bear major risk of compromise from overdose 
complication. 
For the first and third stage, R.M. and J.S. used the specified exclusion and inclusion 
criteria to independently screen all relevant routes of administration for potential 
inclusion. When the reviewers reached different decisions, B.F. acted as the final 
arbitrator for inclusion or exclusion of a route. 
3. RESULTS 
3.1. Shortlisting potential non-injectable routes from analysis of all routes of 
administration 
 From examination of all 112 listed routes of administration (FDA, 1992), four 
were excluded on the basis that they held no analytic relevance (‘unassigned’, 
‘unknown’, ‘other’ and ‘not applicable’). From the remaining 108 categories, a further 
102 were excluded according to the criteria listed in ‘Method’ (see determination in 
Supplementary Material3). For instance, enteral delivery (through the gastro-intestinal 
mucosa) was excluded because of insufficient systemic absorption, since naloxone is 
poorly bioavailable if swallowed due to high first-pass metabolism (Fishman et al., 
1973). After this process, six non-injectable candidate routes remained to be 
considered further (see Table 1). 
 We then removed two of these six routes (see in italics at bottom of Table 1) 
on the basis that they were overarching categories of routes already being 
considered. Thus ‘oropharyngeal’ was removed as substantially overlapping with 
                                                        
3 Supplementary material can be found by accessing the online version of this paper at 
http://dx.doi.org and by entering doi:...  
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‘buccal’ and ‘sublingual’, and ‘transmucosal’ was removed and  considered under the 
specific mucosa (‘buccal’, ‘intranasal’, ‘sublingual’). With regard to the wider range of 
possible transmucosal routes, rectal delivery, which has replaced administration by 
injection for several emergency medications in paediactric care (Lyon and McIntosh, 
1985; NICE, 2009), was specifically not included for further consideration since it is 
unlikely to be acceptable to family and peers for community-based naloxone 
emergency administration to overdose victims. 
3.2. Fuller examination of the four shortlisted potential non-injectable routes 
 We next examined more fully these four potential routes (buccal, nasal, 
sublingual, respiratory/inhalation) based on the literature retrieved from the electronic 
databases. According to the WHO International Clinical Trials Registry Platform, 
nasal naloxone is currently being investigated in clinical trials by the Norwegian 
University of Science and Technology (NCT02307721, NCT01939444), in the US by 
the University of Cincinatti (NCT01912573) and Lightlake Sinclair Ltd. 
(NCT01567670), in Jordan by Mitovie Pharma Ltd (NCT01622504), and in Australia 
at the Sydney Medically Supervised Injecting Centre (ACTRN12611000852954). 
Buccal naloxone is currently being studied at King’s College London in the UK 
(EudraCT 20140001802-16 & 2016-000582-23; see below). No database entries 
were found for study of naloxone via the sublingual or respiratory/inhalation routes. 
We then consider each of these in turn:  
3.2.1 Respiratory (inhalation). We excluded the 'Respiratory (Inhalation)' route as not 
being suitable for further consideration because the victim might no longer be 
breathing (or breathing only very shallowly). Further, current portable devices for 
drug delivery to the lungs could not be used reliably in an emergency situation by 
non-medical personnel (spray or aerosolized naloxone is better considered under the 
‘nasal’ category).  
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3.2.2 Sublingual. For the sublingual route, PubMed identified one pharmacodynamics 
study in opioid-dependent volunteers, where sublingual naloxone precipitated 
withdrawal symptoms in 5 out of 9 participants (Preston et al., 1990). Apart from 
separate work on buprenorphine/naloxone combination, no further investigative work 
for sublingual was identified.  
3.2.3 Nasal. PubMed search yielded 18 studies reporting in vivo administration of 
intranasal naloxone. Preclinical data from rodent studies showed complete 
absorption of nasal naloxone (bioavailability relative to IV: F% = 101%; Hussain et 
al., 1984). In first in-human trials, nasal naloxone was found to elicit withdrawal 
symptoms in opioid-dependent volunteers (Loimer et al., 1992, 1994). Since the early 
2000s, nasal naloxone has been used off-label by ambulance personnel (Barton et 
al., 2005, 2002; Belz et al., 2006; Kelly et al., 2005; Kerr et al., 2009; Merlin et al., 
2010; Robertson et al., 2009; Weber et al., 2012) and in the emergency department 
(Sabzghabaee et al., 2014). More recently, improvised nasal kits (consisting of a pre-
filled naloxone syringe and an atomizer which fits onto the syringe to generate a 
nasal spray) have been provided to opioid users, peers, and families in take-home 
naloxone trials (Doe-Simkins et al., 2009; Dwyer et al., 2015; Walley et al., 2013a, 
2013b), and succesful overdose reversals using improvised nasal kits have also 
been reported for police first responders (Rando et al., 2015). However, the only 
published pharmacokinetics study in humans found intranasal naloxone (2mg/5ml) 
had a relative bioavailability of only 4% (Dowling et al., 2008).  
3.2.4 Buccal. PubMed search identified two preclinical studies on buccal naloxone. In 
rodents, buccal naloxone administration led to high bioavailability (F% = 69-71%) and 
a Tmax of 24 minutes (Hussain et al., 1987; Hussain et al., 1988), whereas in dogs, 
despite buccal Tmax at 18 minutes, bioavailability was low (16%) (Hussain et al., 
1988).  
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 Consequently, only three routes of administration are carried forward for full 
consideration as candidate routes of administration for emergency naloxone by non-
medical personnel: nasal, sublingual and buccal. We now compare all three routes 
more fully against the FDA-identified reference route (injectable naloxone) (Hertz, 
2012).  
3.3. Testing requirements for potential new routes of administration (nasal, sublingual 
and buccal) 
 For all three identified candidate non-injectable routes (nasal, sublingual and 
buccal), investigators and manufacturers need to consider the FDA guidance on 
development of novel naloxone formulations for outpatient use (Hertz, 2012). The 
FDA proposed this strategy mindful of the good safety profile of naloxone: while 
naloxone blocks opiate receptors, it has no pharmacological effect in individuals who 
are not opiate-dependent and do not have any opioids in their system. Moreover, as 
it has no potential of abuse due to lack of euphoriant effect (Brunton, 2010), the 
pharmacokinetics of novel naloxone formulations can thus be safely tested in healthy 
volunteers. According to the FDA guidance (Hertz, 2012), pharmacokinetic studies 
will need to “[e]valuate the relative bioavailability of at least two different doses 
compared to parenteral injection of naloxone (IM, IV or SC). [Studies should] 
[c]ompare a parenteral dose of naloxone of at least 0.4 mg to dose(s) of the new 
product that would be expected to result in similar or greater drug exposure. Target 
plasma naloxone levels [should be] detectable in all subjects for a meaningful 
duration comparable to approved product.”. 
 The FDA guidance (Hertz, 2012) outlines the following key questions 
concerning the bioavailability and usability of a new product:  
1) “If the relative bioavailability is low, will there be adequate efficacy? If the 
relative bioavailability is high, are there implications for the safety profile?” 
2) “Can the product be used by the intended population, i.e. [is] administration 
by someone other than the patient [possible]?” 
For all potential non-injectable naloxone products, it will be important to focus on 
absorption within the first 20-30 minutes. For emergency overdose applications, any 
novel naloxone product will need to be absorbed rapidly into the bloodstream and 
thence across the blood-brain barrier. This is plausible for the nasal, buccal and 
sublingual routes, since they all involve absorption across a mucous membrane 
outside the gastro-intestinal tract. They drain to the peripheral circulation rather than 
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the hepatic portal vein, thus avoiding the hepatic portal system and first-pass 
metabolism in the liver.  
  The nasal route is characterized by high blood perfusion of the nasal mucosa 
which facilitates transmucosal absorption, and drainage mainly occurs into the facial 
veins (Dale et al., 2006; Standring, 2015). The buccal route (from the oral vestibular 
cavity) and the sublingual route both drain into the internal jugular vein via the facial 
veins, and thence rapidly to the brain (Standring, 2015). 
 For nasal drug delivery, an additional nose-to-brain (N2B) connection has 
been hypothesized. It is mooted that drugs could be transported directly into the 
cerebrospinal fluid via the olfactory and trigeminal nerves (Djupesland et al., 2014) 
through the olfactory epithelium (on the roof of the nasal cavity) projecting directly 
into the olfactory bulb. However, human evidence of direct drug transport from the 
nose to the cerebrospinal fluid is currently still lacking (Djupesland et al., 2014; 
Merkus et al., 2003). 
 In addition to these anatomical and pharmacological factors, we need to 
consider the context of emergency overdose reversal (e.g., devices need to be 
portable, accessible, easy to use and also operational on an unconscious supine 
overdose victim) as well as the physical health of the target population, including 
potential damage to, or obstruction of, the relevant mucosa.  
3.3.1 Intranasal. Clinical reports describe use of improvised nasal naloxone kits 
which indicate life-saving benefit in many situations (see Results 3.2). However, for 
non-concentrate nasal kits, there remains uncertainty with regard to the formulation’s 
bioavailability and reliability of clinical effectiveness (Strang et al., 2016). For 
example, Dowling et al. (2008) found that non-concentrate nasal naloxone spray 
(2mg/5mL) had a bioavailability of only 4%, although the authors themselves 
acknowledged that the poor absorption was likely due to the insufficiently 
concentrated formulation. 
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 In two ambulance-based clinical trials, intranasal naloxone had a substantial 
non-response rate: among opioid overdose victims, 26% (using 2mg/5mL nasal 
formulation; Kelly et al., 2005) and 18% (using 2mg/mL nasal formulation; Kerr et al., 
2009) required a second rescue dose of naloxone (the second dose given IM).  
 For a  purpose-developed nasal naloxone spray, a more concentrated 
formulation of naloxone should be used, e.g., at least 5-10x current concentrations, 
a) to overcome the drug loss associated with administration of excessive volumes to 
the nasal cavity and b) to administer naloxone across the recommended dose range 
(i.e. bioequivalent to 0.4-2 mg IV or IM).  
 A significant positive development in this regard is the recent FDA approval of 
a new nasal spray formulation of a concentrated naloxone solution (US territory only) 
(FDA, 2015). Pharmacokinetics data (including dose-equivalence and constancy) on 
concentrated naloxone nasal spray will hopefully become available and it will be 
important to field-test the new product to assess the potential significance of practical 
obstacles, e.g., inter-individual variability, impact of airway blockage or apnea, impact 
of vomitus in the nasal passages or mouth, impact of nasal mucosal damage from 
drug abuse. This is necessary because drug users may have damaged nasal 
mucosa – for example, ulceration, scarring and loss of tissue from repeated cocaine 
use (Peyrière et al., 2013). Absorption may consequently vary substantially between 
individuals, making it difficult to achieve systemic drug levels rapidly and reliably. 
There is also the possibility of interference with nasal absorption from vomiting 
associated with the overdose, thereby rendering the nasal cavity compromised. 
3.3.2 Sublingual: An FDA product application was submitted in 2015 for a sublingual 
naloxone spray (FDAnews, 2015). If the naloxone were to be absorbed rapidly and 
efficiently, then this could be viable. However, there are several concerns regarding 
the suitability of the sublingual route for the emergency administration of naloxone. 
Access to the mucosa under the tongue may be obstructed if the mouth of the 
overdose victim is closed and/or if vomiting has occurred. A sublingual spray would 
13 
 
be difficult to administer, as liquid may be lost to swallowing. Sublingual tablets are 
typically small and would be hard to position. Furthermore, significant inter-subject 
variability of sublingual naloxone delivery and effect was observed in a 
pharmacodynamics study in opioid users (Preston et al., 1990). 
3.3.3 Buccal: Despite lack of human in vivo data for buccal naloxone, we see merit in 
exploration of the option of a solid-form rapid-dispersal buccal tablet formulation. 
Working between the Addictions Department and the Institute of Pharmaceutical 
Science at King’s College London, we have developed a working prototype 
lyophilised tablet of naloxone, suitable for application to the buccal mucosa with rapid 
drug release for absorption (e.g., within 30 seconds; Alqurshi et al., submitted). 
Approval has been received from the Medicines and Healthcare products Regulatory 
Agency (MHRA) in the UK for a first-in-human CTIMP to investigate buccal delivery 
of naloxone (EudraCT number 2014-001802-16), and the Phase-I trial will generate 
pharmacokinetics data of naloxone absorption from the buccal cavity in healthy 
volunteers. This first study is examining absorption of a buccal liquid, and a 
subsequent study (EudraCT number 2016-000582-23) will examine absorption from 
the buccal lyophilized formulation of naloxone which we have developed and 
manufactured (Alqurshi et al., submitted) and whose pharmacokinetics will be 
compared to those with IV and IM injection of the existing licensed naloxone. In this 
way, we will explore dose comparability and draw a comparison between absorption 
of buccal naloxone from solution and from the new lyophilized formulation.  
4. DISCUSSION 
 The development of non-injectable formulations of naloxone is of major 
importance because of the potential for administration by non-medical people in 
emergency situations. Injectable routes work well and are fit for purpose for use by 
medical staff in hospital settings or by ambulance personnel attending a community 
emergency overdose scenario. However, the consideration is different for emergency 
administration by the general public (i.e. without medical training). While family 
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members can be trained and are regularly given such training and emergency 
injectable medications for other potential medical crises (e.g., adrenaline/epinephrine 
for allergy anaphylaxis, insulin for diabetics, etc.), there would nevertheless be 
greater ease of distribution and comfort with emergency administration if an effective 
and reliable non-injectable formulation of naloxone was available.  
 Examination of the extensive list of more than 100 different routes of 
administration identified three plausible non-injectable routes – nasal, sublingual and 
buccal - which warrant proper study. If successful, all three routes could become 
viable, cost-effective future alternatives to the licensed naloxone injection and could 
facilitate effective bystander response to opioid-overdose while minimizing 
associated risk. 
 Consideration and investigation of nasal naloxone is the more advanced area. 
After a decade of community provision of improvised naloxone nasal spray, several 
pharmaceutical companies have recently been developing and testing purpose-made 
naloxone nasal sprays. 
 In November, 2015, FDA approved a first concentrated naloxone nasal spray 
(FDA, 2015) and granted fast-track review to a new drug application for a subligual 
naloxone spray (FDAnews, 2015). In the US at least, the new concentrate nasal 
product is expected to replace improvised nasal kits which - despite lack of regulatory 
testing or evidence of bioavailability - had been introduced in growing numbers since 
the late 2000s.  
 Sublingual medications have been used in medicine to great benefit in 
emergency situations, such as glyceryl trinitrate (GTN) sublingual tablets or spray as 
acute treatment of angina or myocardial infarct. However, the sublingual route may 
be compromised if there is vomit or secretions.   
 No human data exist for buccal naloxone to date, and study of the buccal 
route for naloxone administration is less advanced. However, the buccal route has 
been successfully used to develop non-injectable versions of other medications 
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previously available as injection only. Buccal midazolam (‘Buccolam’) produces rapid 
onset of action and its bioavailability (80%) is slightly superior to nasal midazolam 
(73-75%; Dale et al., 2006; Knoester et al., 2002; Schwagmeier et al., 1998; Taylor et 
al., 2008). Buccolam is now a licensed treatment that parents can administer while 
awaiting professional medical care (MHRA, 2011). There have also been promising 
experimental results with buccal naltrexone delivery in humans (Paderni et al., 2013).  
With regard to feasibility of the three candidate routes (see also Table 1), we 
consider the nasal route to be strong if concentrated solutions are used and provided 
dose-titration schedules can be made possible. We consider the sublingual route to 
be weakest, given that access to the sublingual mucosa may be obstructed in at least 
two scenarios: a) if the mouth of the overdose victim is closed and/or b) if vomiting 
has occurred. We consider the buccal route to hold real potential if rapid absorption 
and good stability can be achieved. 
 The main strength of this review lies in the methodological approach of its 
exhaustive consideration of all FDA-recognized routes of administration. However, 
we cannot rule out the possibility that other non-injectable routes that may in future 
prove feasible for naloxone administration due to technological advances. The scope 
of this review is further limited by the lack of empirical data from pre-clinical or clinical 
studies, which reflects the lack of investment in naloxone product development by 
science and by the pharmaceutical industry. A particular current failing is the 
disconnect between clinical innovation and the need for evidence of bioavailability 
and clinical safety (Strang et al., 2016).  
 With regard to clinical safety, we suggest that the risk of adverse reactions 
should be studied for novel formulations. The dosage of any new formulation will 
need to strike a balance between reversing opioid action without causing severe 
adverse reactions (Hertz, 2012). Reports of the harm caused by naloxone over-
antagonism have been described, and high-dose naloxone formulations with 
increased risk of over-antagonism may also result in negative attitudes from drug 
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users, as previously reported (Neale and Strang, 2015). Similar to testing of the 
maximum tolerated dose in cancer treatment, there may be merit in experimental 
study conducted with opioid-dependent volunteers in order to establish, in a 
population closer to the relevant target population, the non-response rate, dose 
adequacy and the speed with which the novel naloxone formulation reverses central 
opioid action.  
 At least one study has been conducted using a vulnerable population (i.e. 
opioid-dependent prisoners) to assess the pharmacodymanics of nasal naloxone 
(Loimer et al., 1992). However, utmost importance is necessary in design and 
conduct of studies in opioid-dependent volunteers with attention to the informed 
consent procedure to ensure that all interested subjects are properly informed and 
sufficiently protected from potential harm. Community consultation with service user 
groups has already been initiated to discuss what potential study designs would be 
feasible and ethically sound.  
 At a minimum, any licensed new naloxone product should be carefully 
monitored for potential side effects and non-response rate once it enters the market, 
and take-home naloxone recipients should be actively encouraged to report any 
adverse reactions that may occur.    
 Deaths from opioid overdose can be prevented through prompt administration 
of naloxone, and there is increasing pre-provision of naloxone for emergency use by 
non-medical personnel. However, worldwide, provision is held back by reliance on 
injectable formulations. From application of the FDA criteria and review of all 112 
categories for routes of administration, we identify only three routes of possible non-
injectable naloxone administration which meet the FDA criteria: nasal, sublingual and 
buccal. Improvised nasal naloxone kits have been distributed in many cities, and a 
first concentrate nasal spray was granted FDA approval in November, 2015, although 
pharmacokinetic data are still not available in the peer-reviewed domain and inter-
individual dose variability needs to be studied. The buccal route may have a different 
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pharmacokinetic profile and may have the advantage of ease of carriage and 
administration as well as not being obstructed by opiate-induced vomiting. After 40 
years of opioid overdose treatment by naloxone injection, non-injectable naloxone 
products are finally being explored, and nasal, sublingual and buccal routes of 
delivery warrant proper exploration and testing.  
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Figure Captions 
Figure 1. Selection process of candidate routes of administration. 
Figure 2. PRISMA flow diagram of study selection process. 
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Tables 
Table 1 | Third stage of selection of potential routes of administration: inclusion criteria 
   Inclusion criteria 
NAME DEFINITION 
FDA 
CODE 
Suitable for overdose 
crisis 
situation 
No risk of compromise from 
overdose complication 
BUCCAL Administration directed toward the cheek, generally from within the mouth. 030 X X 
NASAL Administration to the nose; administered by way of the nose. 014 X possible impairment due to O/D 
vomit or secretions 
SUBLINGUAL Administration beneath the tongue. 024 X possible impairment due to O/D 
vomit or secretions or due to closed 
mouth 
RESPIRATORY 
(INHALATION) 
Administration within the respiratory tract by inhaling orally or nasally for 
local or systemic effect. 
136 not viable as O/D victim 
not breathing or only 
shallowly 
X 
With the following routes subsumed into the above four routes: 
OROPHARYNGEAL Administration directly to the mouth and pharynx. 410 absorption likely to be 
too slow 
possible impairment due to O/D 
vomit or secretions 
TRANSMUCOSAL Administration across the mucosa. 122  - as for buccal -  
